Cyclone® KIUBE

IBA low & mid-energy cyclotrons installed across the world

• 

  • 20/03/2026

  Telix selects IBA Cyclone® KIUBE to support manufacturing expansion in the U.S.

  Louvain-la-Neuve, Belgium - March 20, 2026 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, today announced it has signed a contract with Telix Pharmaceuticals Limited (Telix; ASX: TLX, NASDAQ: TLX), a precision oncology company, for the initial order of four Cyclone^® KIUBE cyclotrons at standard IBA conditions¹. The systems will be installed at select RLS Radiopharmacies (RLS) sites in the United States (U.S.).
   

  This investment supports Telix’s strategic expansion of its U.S. manufacturing footprint with the goal of strengthening supply chain resilience and to enable in-house production of critical therapeutic and diagnostic isotopes and radiopharmaceuticals for cancer care. The agreement also contributes to the growth of IBA RadioPharma Solutions, reinforcing its leading position in the market. By combining IBA’s cyclotron expertise with Telix’s distribution and production footprint, this collaboration strengthens the collective capacity to meet the rising demand for sophisticated PET imaging tracers and other integrated theranostic solutions.
   

  Telix selected the Cyclone^® KIUBE 180 for its high-current capacity, industrial reliability, and capacity for future upgrades. Each cyclotron will be equipped with QUANTM^® Irradiation System (QIS^®), the latest irradiation system developed by ARTMS, a wholly-owned subsidiary of Telix Pharmaceuticals. Together, these technologies will enable cGMP-compliant production of critical radio-metals including Gallium-68 (⁶⁸Ga), Zirconium-89 (⁸⁹Zr), Technetium‐99m (⁹⁹mTc) and Copper-64 (⁶⁴Cu) initially. The integration of this advanced targetry hardware represents a key technical milestone, enabling efficient, high-yield, localized production of high-demand isotopes, reducing reliance on external suppliers and mitigating supply chain risk.
   

  Charles Kumps, President of IBA RadioPharma Solutions, commented: “We are proud to deepen our partnership with Telix. By combining our cyclotron leadership with Telix’s innovative approach and ARTMS technology, we are working to accelerate the availability of advanced diagnostic tools. This collaboration exemplifies our mission to protect, enhance, and save lives by making nuclear medicine more accessible worldwide and delivering meaningful impact for patients.”
   

  Chad Watkins, General Manager Isotope Strategy at Telix, added: “Expanding our isotope production and manufacturing capabilities at RLS with IBA’s technology and the ARTMS QIS system is a critical step in improving patient outcomes. This investment in the RLS/Telix network will help ensure that clinicians have reliable, nationwide access to the precision tools they need to diagnose and treat cancer more effectively.”
   

  ¹This contract, signed at the end of 2025, will be booked in IBA’s 2025 order intake. In accordance with its financial communication policy, IBA announces the conclusion of commercial contracts after receiving the first instalment.
   

  Cautionary Statement Regarding Forward-Looking Statements

  This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

  More details
• 

  • 19/02/2026

  IBA and Shreeji sign multi-site agreement for four cyclotrons

  Louvain-la-Neuve, Belgium - 19 February 2026 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, and Shreeji (Shreeji Imaging and Diagnostic Centre Pvt. Ltd.), a leading Indian manufacturer and distributor of fluorodeoxyglucose (FDG) and positron emission tomography (PET) radiopharmaceuticals, have signed a multi-site agreement for the delivery and installation of four mid-energy Cyclone^® KIUBE 300 cyclotrons. The systems will be deployed in Ahmedabad, Nagpur, Kochi and Bhubaneswar to support the industrial-scale production of fluorine-18 (F-18) labelled compounds and other PET radiopharmaceuticals. The contract is valued at €5–7 million.
   

  India’s PET imaging market is expanding fast as access moves beyond the largest cities, increasing pressure on secure tracer supply. Shreeji is responding by adding four Cyclone^® KIUBE 300 cyclotrons to its existing manufacturing network, bringing high-quality F-18 production closer to patients and reducing logistics risk while creating additional capacity for new tracers. The agreement further strengthens IBA’s presence in India and supports its mission to broaden timely, dependable access to PET diagnostics in cancer care, while building a high-quality installed base supporting long-term service and upgrades.
   

  Shreeji selected the Cyclone^® KIUBE for its high beam current capability, industrial reliability and clear upgrade path that keeps production flexible as tracer portfolios evolve. The platform enables sustained, GMP-compliant F-18 production today, while its efficiency contains operating costs across multiple sites and supports scalable, sustainable growth.
   

  “At IBA, we are committed to having a positive societal impact everywhere in the world by enhancing access to cutting-edge care, and we are proud to advance that mission through this contract with Shreeji,” said Charles Kumps, President of IBA RadioPharma Solutions. “India's nuclear medicine community is growing fast, and reliable, local manufacturing is fundamental to patient access. Partnering with Shreeji to deploy multiple Cyclone^® KIUBE systems creates a resilient, multi-node network that supports the next phase of PET growth in India while improving consistency of supply for clinicians and their patients.”
   

  “IBA’s Cyclone^® KIUBE gives us the capacity and flexibility we need to serve more centers, more reliably,” said Amit Maniar, Director, Shreeji., “With four new systems coming online, we are significantly boosting domestic production, strengthening supply‑chain resilience, and accelerating our ability to introduce next‑generation tracers that enhance patient care. We expect this expansion to stimulate latent PET demand by ensuring cost‑effective, dependable access to the full spectrum of F‑18 isotopes and emerging novel isotopes. It also positions us to support the next wave of healthcare growth across emerging hubs, while adding important redundancy to our network to ensure consistent, nationwide service.”

  More details
• 

  • 18/01/2024

  The 100^th Cyclone® KIUBE cyclotron

  Major milestone reached with the sale of the 100th Cyclone® KIUBE cyclotron! With an unmatched production capacity of up to 300 μA per run, it's solidifying its status as the industry's leading force! Unmatched in versatility and reliability, the Cyclone® KIUBE continues to set the standard for excellence. Proud to be at the forefront of innovation and meeting the evolving needs of our users.

  More details